Title : Phytochemical-based nanoformulation against Hepatocellular carcinoma
Abstract:
Hepatocellular carcinoma (HCC) is one of the deadliest malignancies being the 3rd leading cause of cancer death worldwide. The current treatment of HCC fails to provide tumor specificity, causing many systemic toxicities and poor overall survival benefits especially for patients with advanced stages. Sorafenib, an oral multikinase inhibitor, is the only FDA-approved drug for HCC. However, a wide array of adverse effects limits its use along with the development of resistance. Natural medicines have proved to have significant anti-cancer properties. The major factor that limits their clinical utility is their pharmacokinetic and bioavailability limitations. These limitations can be overcome using an appropriate formulation that can retain its medicinal properties, thereby enhancing its pharmacokinetic properties.. Green synthesized nanoparticles offer significant anticancer effects along with minimal systemic toxicities because of their site-specific delivery into the tumor microenvironment. They can be a promising futuristic tool for the treatment of HCC if properly validated with clinical studies.
